Saidi Hamza, Smart Luke R, Kamugisha Erasmus, Ambrose Emmanuela E, Soka Deogratias, Peck Robert N, Makani Julie
Muhimbili Wellcome Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Department of Medicine, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Hematology. 2016 May;21(4):248-256. doi: 10.1080/10245332.2015.1101976. Epub 2016 Feb 17.
Tanzania has the third highest birth rate of sickle cell anaemia (SCA) in Africa, but few studies describe severity of complications or available treatments, especially in Northwest Tanzania around Lake Victoria where the sickle gene is most prevalent. This is a report of the spectrum of clinical disease and range of interventions available at Bugando Medical Centre (Bugando) in Northwest Tanzania in Africa.
A cross-sectional study was carried out in Bugando between 1 August 2012 and 30 September 2012. Children (<15 years old) with SCA attending Bugando were sequentially enrolled. A trained research assistant completed a Swahili questionnaire with the parent or guardian of each participant concerning demographic information, clinical features of disease, and treatments received.
Among the 124 participants enrolled, the median age was 6 years (interquartile range [IQR] 4-8.5), and only 13 (10.5%) were < 3 years old. Almost all participants (97.6%) had a prior history of a vaso-occlusive episode, 83 (66.9%) had prior acute chest syndrome, and 21 (16.9%) had prior stroke. In the preceding 12 months, 120 (96.8%) had been hospitalized, and a vaso-occlusive episode was the most common reason for hospitalization (35.5%). Prescriptions for folic acid (92.7%) and malaria prophylaxis (84.7%) were common, but only one had received a pneumococcal vaccine, and none had received hydroxyurea or prophylactic penicillin.
Children with SCA receiving care in Tanzania are diagnosed late, hospitalized frequently, and have severe complications. Opportunities exist to improve care through wider access to screening and diagnosis as well as better coordination of comprehensive care.
坦桑尼亚是非洲镰状细胞贫血(SCA)出生率第三高的国家,但很少有研究描述并发症的严重程度或可用的治疗方法,特别是在维多利亚湖周边的坦桑尼亚西北部,那里镰状基因最为普遍。本文报告了非洲坦桑尼亚西北部布甘多医疗中心(布甘多)临床疾病的范围和可用的干预措施。
2012年8月1日至2012年9月30日在布甘多进行了一项横断面研究。在布甘多就诊的患有SCA的儿童(<15岁)被依次纳入研究。一名经过培训的研究助理与每位参与者的父母或监护人一起完成了一份斯瓦希里语问卷,内容涉及人口统计学信息、疾病的临床特征以及接受的治疗。
在纳入的124名参与者中,中位年龄为6岁(四分位间距[IQR]4 - 8.5),只有13名(10.5%)年龄小于3岁。几乎所有参与者(97.6%)都有血管闭塞发作史,83名(66.9%)有急性胸综合征史,21名(16.9%)有中风史。在之前的12个月里,120名(96.8%)曾住院,血管闭塞发作是住院最常见的原因(35.5%)。叶酸(92.7%)和疟疾预防用药(84.7%)的处方很常见,但只有一人接种过肺炎球菌疫苗,没有人接受过羟基脲或预防性青霉素治疗。
在坦桑尼亚接受治疗的SCA儿童诊断较晚,频繁住院,且有严重并发症。通过更广泛地开展筛查和诊断以及更好地协调综合治疗,存在改善治疗的机会。